Acute HIV Infection. Acute

Size: px
Start display at page:

Download "Acute HIV Infection. Acute"

Transcription

1 Acute HIV In nfection n Acute HIV Infection Jintanat t Ananworanich, MD, PhD Investigator, AFRIMS (Armed Forces Research Institute of Medical Sciences) Chief of SEARCH Deputy Director in Scientific Affairs, HIV-NAT, The Thai Red Cross AIDS Research Centre Jintanat.a@searchthailand.org ; Jintanat.a@hivnat.org

2 Outline Acute HIV In nfection n Immunopathogenesis Clinical manifestation Diagnosis Consideration for treatment RV254 Establish a cohort of acute HIV infected subjects in Thailand

3 Acute HIV In nfection nwhy is acute HIV infection important? Understand early immunologic and virologic Design effective events preventive HIV vaccine Early treatment to preserve T cells and limit reservoir Achieve functional cure = Drug free remission Diagnose HIV at its height ht of transmission potential Limit HIV spread

4 Immunopathogenesis of Acute HIV Infection Acute HIV Infectionn

5 Brenchley JM, et al. 2004:200 (6):P749-59

6 Innate and adaptive immunity after HIV transmission McMichael AJ, Nature Review 2010

7 Window of Opportunity Usually mediated by a single virion McMichael AJ, Nature Review 2010

8 Diagnosis of Acute HIV Infection Acute HIV Infectionn

9 Acute HIV In nfection n Fiebig Laboratory Staging gof Acute HIV Infection Cohen MS, J Infect Dis 2010

10 Acute HIV In nfection ndiagnosis of Acute HIV Infection Fiebig I/II Fiebig III/IV HIV EIA (4 th generation EIA) Negative Positive Nucleic acid testing 2 nd generation EIA Negative Positive Negative Positive No HIV infection Acute HIV infection Chronic HIV infection Procedures in RV254

11 Acute HIV In nfection n Clinical Manifestation of Acute HIV Infection

12

13 Consideration for Treatment Acute HIV Infectionn

14 Acute HIV In nfection nconsideration for Treatment Pros Cons Preservation of immune Toxicity functions Drug resistance Improve surrogate markers of HIV disease Quality of life Limit transmission Unknowns Will it alter clinical i l disease? Is this a life long treatment? Can patient interrupt treatment? Bell SK, J Infect Dis 2010

15 Summary Acute HIV In nfection n The first 3 weeks of infection offers a window of opportunity to contain HIV through novel interventions CD4+ T cell depletion particularly in the gut occurs very early in HIV infection The majority of HIV infected persons display symptoms of acute retroviral syndrome (fever, rash, sore throat) which is usually misdiagnosed Antiretroviral treatment is optional. Although it may limit immunedestructionand viral reservoir, there is currently no clear clinical benefit to early treatment Knowledge of acute HIV infection is crucial to the design of effective prevention and treatment. Subjects should be encouraged to enroll in clinical trials y

16 15 October 2010

17 RV254 Acknowledgement Acute HIV In nfection n AFRIMS Alexandra Schuetz Mark desouza Rapee Trichavaroj Vatcharain Assawadarachai Yuwadee Phuangngern Wiriya Rutvisuttinunt Nantana Tantibul WRAIR Jerome Kim Nelson Michael Mary Marovich Jeff Currier Sodsai Tovanabutra Merlin Robb Silvia Kim Thai Red Cross/SEARCH/HIV NAT/Chula Praphan Phanuphak Nipat Teeratakulpisarn Rungsun Rerknimitr Nittaya Phanuphak Thep Chalermchai h Duanghathai Suttichom Nitiya Chomchey Thai US CDC collaboration Somprartthana Rtt Rattanamanee Panadda Sawangsinth Bessara Nuntapinit Frits van Griensven Pairoa Praihirunkit Siriwat Akapirat Supaporn Chaikummao James Fletcher Wanwarang Khobchit Wipas Wimonsate Sasiwimol i lubolyam Sakuna Suksawad NIAID Sukalya Lerdlum Irini Sereti Ajchariyarat Sangdara Mantana pothisri Jacob bet Estes Kultida Poltavee Wiriyaporn ii Ridtitid i Jessica Hodge Hathairat Savadsuk Umaporn Siangphoe Michael Yao Suwittra Chaemchuen Huntington Memorial Adam Rupert Napaporn Sailasuta Joseph Chiu Frank Maldarelli Robert Paris Industry Robin Dewar Viseth Ngauy Gilead (TDF, FTC) UCSF VGTI Rafick Sekaly Merck (EEV, RAL) Victor Valcour Nicolas Chomont Pfizer (MVC) Claire Vandergeeten Monogram (Trofile)

IAS 2016 Towards an HIV Cure Symposium Durban, South Africa.

IAS 2016 Towards an HIV Cure Symposium Durban, South Africa. Effect of vorinostat, hydroxychloroquine and maraviroc combination therapy on viremia following treatment interruption in individuals treated during acute HIV infection Eugène Kroon, Jintanat Ananworanich,

More information

Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection

Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection Jintanat Ananworanich 1,2,3,4,5 *, Alexandra Schuetz 5,6, Claire Vandergeeten

More information

MHRP Studies in Early Treatment and The Journey towards HIV Remission

MHRP Studies in Early Treatment and The Journey towards HIV Remission MHRP Studies in Early Treatment and The Journey towards HIV Remission Merlin L. Robb, MD Deputy Director of MHRP for Clinical Research Director, HJF Component of MHRP US Military HIV Research Program mrobb@hivresearch.org

More information

Title: Distinct Biomarker Signatures in HIV Acute Infection Associate with. Viral Dynamics and Reservoir Size. Supplemental Material

Title: Distinct Biomarker Signatures in HIV Acute Infection Associate with. Viral Dynamics and Reservoir Size. Supplemental Material 1 2 Title: Distinct Biomarker Signatures in HIV Acute Infection Associate with Viral Dynamics and Reservoir Size 3 Supplemental Material 1 11 12 13 1 1 1 1 1 1 2 21 22 23 2 Authors: Jeffrey E. Teigler

More information

Cure: Early Detection and Early Treatment"

Cure: Early Detection and Early Treatment Cure: Early Detection and Early Treatment" ECHO (RV217) and RV 254 Merlin L. Robb, MD, Dr. Jintanat Ananworanich, and Dr. Jerome Kim and Dr. Nelson Michael 4 th International Workshop on HIV & Women 13-14

More information

State of the ART: HIV Cure where are we now and. where are we going? Jintanat Ananworanich, MD, PhD MHRP

State of the ART: HIV Cure where are we now and. where are we going? Jintanat Ananworanich, MD, PhD MHRP State of the ART: HIV Cure where are we now and ì where are we going? Jintanat Ananworanich, MD, PhD Associate Director for Therapeu1cs Research US Military HIV Research Program (MHRP) Maryland, USA Deputy

More information

Promoting early detection of HIV and anal dysplasia in Thai men who have sex with men Phanuphak, N.

Promoting early detection of HIV and anal dysplasia in Thai men who have sex with men Phanuphak, N. UvA-DARE (Digital Academic Repository) Promoting early detection of HIV and anal dysplasia in Thai men who have sex with men Phanuphak, N. Link to publication Citation for published version (APA): Phanuphak,

More information

Change in Brain Magnetic Resonance Spectroscopy after Treatment during Acute HIV Infection

Change in Brain Magnetic Resonance Spectroscopy after Treatment during Acute HIV Infection Change in Brain Magnetic Resonance Spectroscopy after Treatment during Acute HIV Infection The Harvard community has made this article openly available. Please share how this access benefits you. Your

More information

MHRP. Outline. Is HIV cure possible? HIV persistence. Cure Strategies. Ethical and social considerations. Short video on patients perspectives on cure

MHRP. Outline. Is HIV cure possible? HIV persistence. Cure Strategies. Ethical and social considerations. Short video on patients perspectives on cure Outline Is HIV cure possible? Ø HIV persistence Cure Strategies Ethical and social considerations Short video on patients perspectives on cure A Case of Cure Off ART Treatment Mechanism Lesson The Berlin

More information

RESEARCH NOTE USE OF DRIED BLOOD SPOTS FOR HIV-1 GENOTYPING IN SOUTHEAST ASIA: THAILAND EXPERIENCE

RESEARCH NOTE USE OF DRIED BLOOD SPOTS FOR HIV-1 GENOTYPING IN SOUTHEAST ASIA: THAILAND EXPERIENCE RESEARCH NOTE USE OF DRIED BLOOD SPOTS FOR HIV-1 GENOTYPING IN SOUTHEAST ASIA: THAILAND EXPERIENCE Wiriya Rutvisuttinunt 1, Miguel A Arroyo 1,3,4, Vatcharain Assawadarachai 1, Kultida Poltavee 1, Francine

More information

Early Antiretroviral Therapy

Early Antiretroviral Therapy Early Antiretroviral Therapy HIV Cure Research Training Curriculum HIV and Cure Early ART Presented by: Jintanat Ananworanich, MD, PhD June 2016 The HIV CURE research training curriculum is a collaborative

More information

HIV reservoirs in the brain: Where, when, how, and what do they mean for our patients?

HIV reservoirs in the brain: Where, when, how, and what do they mean for our patients? HIV Reservoirs in the Brain: Where, When, How, and What Do They Mean for Our Patients? Serena S. Spudich, MD, MA Professor of Neurology Yale University New Haven, Connecticut FORMATTED: // HIV reservoirs

More information

Initiation of ART during Early Acute HIV Infection Preserves Mucosal Th17 Function and Reverses HIV-Related Immune Activation

Initiation of ART during Early Acute HIV Infection Preserves Mucosal Th17 Function and Reverses HIV-Related Immune Activation Initiation of ART during Early Acute HIV Infection Preserves Mucosal Th17 Function and Reverses HIV-Related Immune Activation Alexandra Schuetz 1,2 *, Claire Deleage 3, Irini Sereti 4, Rungsun Rerknimitr

More information

Effects of Treatment During Acute HIV Infection on HIV Persistence

Effects of Treatment During Acute HIV Infection on HIV Persistence ì Effects f Treatment During Acute HIV Infectin n HIV Persistence Jintanat Ananwranich, MD, PhD Assciate Directr fr Therapeutics Research US Military HIV Research Prgram jananwranich@hivresearch.rg On

More information

ALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen. Results of the Thai HIV Vaccine Trial, RV144

ALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen. Results of the Thai HIV Vaccine Trial, RV144 ALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen Results of the Thai HIV Vaccine Trial, RV144 SupachaiRerks-Ngarm, PunneePittisutthithum, SorachaiNitayaphan, JaranitKaewkungwal,

More information

Acute tubular nephropathy in a patient with acute HIV infection: review of the literature

Acute tubular nephropathy in a patient with acute HIV infection: review of the literature Ananworanich et al. AIDS Research and Therapy 2014, 11:34 CASE REPORT Acute tubular nephropathy in a patient with acute HIV infection: review of the literature Open Access Jintanat Ananworanich 1,2,3,4*,

More information

Immunogenicity of ALVAC HIV (vcp1521) and AIDSVAX B/E Prime Boost Vaccination in RV144, Thai Phase III HIV Vaccine Trial

Immunogenicity of ALVAC HIV (vcp1521) and AIDSVAX B/E Prime Boost Vaccination in RV144, Thai Phase III HIV Vaccine Trial Immunogenicity of ALVAC HIV (vcp1521) and AIDSVAX B/E Prime Boost Vaccination in RV144, Thai Phase III HIV Vaccine Trial M. de Souza, R. Trichavaroj, A. Schuetz, W. Chuenarom, Y. Phuang ngern, S. Jongrakthaitae,

More information

Serena S. Spudich, MD Professor of Neurology Yale University New Haven, Connecticut

Serena S. Spudich, MD Professor of Neurology Yale University New Haven, Connecticut HIV Reservoirs in the Brain: Where, When, How, and What Do They Mean for Our Patients? Serena S. Spudich, MD Professor of Neurology Yale University New Haven, Connecticut FORMATTED: // Financial Relationships

More information

Edwards-Jackson et al. AIDS Research and Therapy 2012, 9:38

Edwards-Jackson et al. AIDS Research and Therapy 2012, 9:38 Edwards-Jackson et al. AIDS Research and Therapy 2012, 9:38 RESEARCH Open Access HIV serostatus disclosure is not associated with safer sexual behavior among HIV-positive men who have sex with men (MSM)

More information

HIV remission: viral suppression in the absence of ART. Sarah Fidler Brian Gazzard Lecture BHIVA 2016

HIV remission: viral suppression in the absence of ART. Sarah Fidler Brian Gazzard Lecture BHIVA 2016 HIV remission: viral suppression in the absence of ART Sarah Fidler Brian Gazzard Lecture BHIVA 2016 Disclosures: My institution receives funding for research from MSD, GSK, ViiV, Gilead Summary of talk

More information

HIV 1 Preventive Vaccine Regimen. Community based Trial in Thailand V 144. for the MOPH TAVEG Collaboration

HIV 1 Preventive Vaccine Regimen. Community based Trial in Thailand V 144. for the MOPH TAVEG Collaboration V ALVAC HIV and AIDSVAX B/E Prime Boost HIV 1 Preventive Vaccine Regimen Final Results of the Phase III Community based Trial in Thailand Supachai Rerks Ngarm, Punnee Pittisutthithum, Sorachai Nitayaphan,

More information

Dr Jintanat Ananworanich

Dr Jintanat Ananworanich BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Jintanat Ananworanich US Military HIV Research Program in Bethesda Maryland, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,

More information

Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection

Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection Brief Communication https://doi.org/1.138/s41591-18-26-6 Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection Donn J. Colby 1,

More information

Complete Transcriptome Analysis of Latently Infected CD4 + T Cells

Complete Transcriptome Analysis of Latently Infected CD4 + T Cells Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 Complete Transcriptome Analysis of Latently Infected CD4 + T Cells Fabio Romerio Institute of Human Virology University of Maryland School

More information

Acquired HIV Drug Resistance in children in Asia

Acquired HIV Drug Resistance in children in Asia Acquired HIV Drug Resistance in children in Asia Jintanat Ananworanich, MD, PhD Pediatrician/Immunologist Deputy Director in Scientific Affairs, HIV-NAT Chief, SEARCH The Thai Red Cross AIDS Research Centre

More information

HIV Basics: Pathogenesis

HIV Basics: Pathogenesis HIV Basics: Pathogenesis Michael Saag, MD, FIDSA University of Alabama, Birmingham Director, Center for AIDS Research ACTHIV 2011: A State-of-the-Science Conference for Frontline Health Professionals Learning

More information

JAY A. NELSON, PH.D. Executive Director and Vice President

JAY A. NELSON, PH.D. Executive Director and Vice President JAY A. NELSON, PH.D. Executive Director and Vice President TRANSLATING RESEARCH INTO HEALTH Jay A. Nelson, Ph.D., is the founder and Executive Director of Vaccine & Gene Therapy Institute of Florida (VGTI-FL)

More information

Impact of early cart in the gut during acute HIV infection

Impact of early cart in the gut during acute HIV infection Downloaded from http:// on February 8, 2018. https://doi.org/10.1172/jci.insight.87065 Impact of early cart in the gut during acute HIV infection Claire Deleage, 1 Alexandra Schuetz, 2,3 W. Gregory Alvord,

More information

HIV remission after discontinuing ART: is it achievable?

HIV remission after discontinuing ART: is it achievable? HIV remission after discontinuing ART: is it achievable? Jintanat Ananworanich, MD, PhD Associate Director for Therapeutics Research US Military HIV Research Program Maryland, USA jananworanich@hivresearch.org

More information

Sangamo BioSciences Presents Phase 2 Clinical Data From Two SB-728-T HIV Studies

Sangamo BioSciences Presents Phase 2 Clinical Data From Two SB-728-T HIV Studies December 11, 2015 Sangamo BioSciences Presents Phase 2 Clinical Data From Two SB-728-T HIV Studies Preliminary Data Suggest Adenoviral Delivery Method Superior for Immune Stimulation and Control of Viral

More information

Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys

Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Dan H. Barouch, M.D., Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Ragon Institute of MGH, MIT,

More information

Inves&gación básica y curación del VIH-1

Inves&gación básica y curación del VIH-1 Inves&gación básica y curación del VIH-1 Javier Mar&nez-Picado 24 th Conference on Retroviruses and Opportunis6c Infec6ons UNIVERSITAT DE VIC Empezamos bien cart: How Early is Early Enough? Sáez-Cirion

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Robb ML, Eller LA, Kibuuka H, et al. Prospective study of acute

More information

Additional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T

Additional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T September 8, 2014 Sangamo BioSciences Announces Presentation At ICAAC of New Clinical Data Demonstrating Sustained Functional Control of Viremia in Multiple HIV- Infected Subjects Treated with SB-728-T

More information

HIV cure strategies: interventions, endpoints and ethics

HIV cure strategies: interventions, endpoints and ethics HIV cure strategies: interventions, endpoints and ethics Professor Sharon R Lewin, FRACP, PhD, FAHMS Fourth Joint Conference of BHIVA with BASSH, April 17-20, Edinburgh International Conference Centre,

More information

HIV Clinical Update- HIV prevention

HIV Clinical Update- HIV prevention HIV Clinical Update- HIV prevention 18 th Australian and New Zealand Conference on Haemophilia and Rare Bleeding Disorders, Melbourne October 13 th 2017 Edwina Wright Disclosures None in the past 12 months

More information

NEWS FROM THE U.S. MILITARY HIV RESEARCH PROGRAM AT THE WALTER REED ARMY INSTITUTE OF RESEARCH

NEWS FROM THE U.S. MILITARY HIV RESEARCH PROGRAM AT THE WALTER REED ARMY INSTITUTE OF RESEARCH mhrp exchange U.S. MILITARY HIV RESEARCH PROGRAM Volume 2, Issue 3 Fall 2014 NEWS FROM THE U.S. MILITARY HIV RESEARCH PROGRAM AT THE WALTER REED ARMY INSTITUTE OF RESEARCH MHRP Congratulates COL Jerome

More information

Planned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP

Planned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP Planned Vaccine Trials to Follow-up on RV 144 Merlin Robb, MD Deputy Director for Clinical Research MHRP Planned studies are mutually reinforcing and will amplify public health impact and regional relevance

More information

Preventive and therapeutic HIV vaccines. Markus Bickel Infektiologikum Frankfurt

Preventive and therapeutic HIV vaccines. Markus Bickel Infektiologikum Frankfurt Preventive and therapeutic HIV vaccines Markus Bickel Infektiologikum Frankfurt No conflicts to declare Disclosures Background FAQ: by patients and colleagues Publication about promising results, especially

More information

HIV 101: Fundamentals of HIV Infection

HIV 101: Fundamentals of HIV Infection HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able

More information

With over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the

With over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the Towards an HIV Cure Steven G. Deeks, MD Professor of Medicine in Residence HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 22, 2013 1 With over 20 drugs and several

More information

Working Group#1: Trial Endpoints, Biomarkers & Definitions

Working Group#1: Trial Endpoints, Biomarkers & Definitions Working Group#1: Trial Endpoints, Biomarkers & Definitions Forum HIV Cure Project: Focus on The Regulatory Pathway June 17, 2014 www.hivforum.org Comments from co-chairs john mellors and mike miller www.hivforum.org

More information

IAS 2013 Towards an HIV Cure Symposium

IAS 2013 Towards an HIV Cure Symposium In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500 CD4/mm 3 achieves better HIV-1 reservoirs' depletion and T-cell count restoration IAS 2013 Towards an HIV Cure

More information

12. Cui L; Yan G; Sattabongkot J; Chen B; Cao Y; Fan Q; Parker D; Sirichaisinthop J; Su XZ; Yang H; Yang Z; Wang B; Zhou G. Challenges and prospects

12. Cui L; Yan G; Sattabongkot J; Chen B; Cao Y; Fan Q; Parker D; Sirichaisinthop J; Su XZ; Yang H; Yang Z; Wang B; Zhou G. Challenges and prospects PUBLICATIONS 2012 1. Aldstadt J; Yoon IK; Tannitisupawong D; Jarman RG; Thomas SJ; Gibbons RV; Uppapong A; Iamsirithaworn S; Rothman AL; Scott TW; Endy T. Space-time analysis of hospitalised dengue patients

More information

Approaching a Cure Daniel R. Kuritzkes, MD

Approaching a Cure Daniel R. Kuritzkes, MD Approaching a Cure Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker is a consultant and/or has received speaking honoraria

More information

The Third D: Long Term Solutions to End the Epidemic. Mitchell Warren Executive Director, AVAC 12 February 2014

The Third D: Long Term Solutions to End the Epidemic. Mitchell Warren Executive Director, AVAC 12 February 2014 The Third D: Long Term Solutions to End the Epidemic Mitchell Warren Executive Director, AVAC 12 February 2014 Key clinical trial milestones: HIV vaccine research First HIV vaccine trial opens Phase

More information

BEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy

BEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy BEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy We are pleased to announce that the National Institutes of Health (NIH) has awarded nearly $23 million to co-principal

More information

HIV Diversity in East Africa

HIV Diversity in East Africa HIV Diversity in East Africa Kayvon Modjarrad, M.D., Ph.D. 16 March 2015 The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army or the Department

More information

HIV DNA reservoir increases risk for cognitive disorders in cart-naive patients

HIV DNA reservoir increases risk for cognitive disorders in cart-naive patients Washington University School of Medicine Digital Commons@Becker Open Access Publications 2013 HIV DNA reservoir increases risk for cognitive disorders in cart-naive patients David B. Clifford Washington

More information

An understanding of host-virus interactions in early acute HIV-1 infection (AHI) is. crossm

An understanding of host-virus interactions in early acute HIV-1 infection (AHI) is. crossm VIROLOGY crossm Identification of Acute HIV-1 Infection by Hologic Aptima HIV-1 RNA Qualitative Assay Mark M. Manak, a,b Leigh Anne Eller, a,b Jennifer Malia, a Linda L. Jagodzinski, a Rapee Trichavaroj,

More information

Identification of acute HIV-1 infection by Hologic Aptima HIV-1 RNA Qualitative Assay

Identification of acute HIV-1 infection by Hologic Aptima HIV-1 RNA Qualitative Assay JCM Accepted Manuscript Posted Online 19 April 217 J. Clin. Microbiol. doi:1.1128/jcm.431-17 Copyright 217 Manak et al. This is an open-access article distributed under the terms of the Creative Commons

More information

HIV/Sexual Health Clinical Education Session

HIV/Sexual Health Clinical Education Session HIV/Sexual Health Clinical Education Session http://courses.ashm.org.au/hiv/hiv-sexual-health-clinical-education-session/ About These Slide These slides may not be published, posted online, or used in

More information

About the MODERN study About maraviroc

About the MODERN study About maraviroc ViiV Healthcare presents phase III data comparing once-daily maraviroc in combination with darunavir/ritonavir with emtricitabine/tenofovir plus darunavir/ritonavir in treatment-naïve adults with HIV-1

More information

30 Years of Thai US Collaboration Charles H. Hoke, Jr., MD

30 Years of Thai US Collaboration Charles H. Hoke, Jr., MD About the Collaborators About this book Many people supported the work described in this book. Children, parents, teachers, principals, community health workers, community leaders, provincial leaders,

More information

Adherence to ART in HIV-infected children in Kenya, South Africa, and Thailand

Adherence to ART in HIV-infected children in Kenya, South Africa, and Thailand Adherence to ART in HIV-infected children in Kenya, South Africa, and Thailand Rachel C. Vreeman, MD, MS Director of Research, IU Center for Global Health Associate Professor of Pediatrics Indiana University

More information

Can HIV be cured? (how about long term Drug free remission?)

Can HIV be cured? (how about long term Drug free remission?) Can HIV be cured? (how about long term Drug free remission?) Shirin Heidari International AIDS Society EC Think Tank meeting 27-28 October 2010 Luxemburg HAART can control HIV, cannot eradicate it Life

More information

11/7/2012. HIV disease: Chronic Disease Patients are aging with their HIV disease on effective antiretroviral therapy (ART)

11/7/2012. HIV disease: Chronic Disease Patients are aging with their HIV disease on effective antiretroviral therapy (ART) The Journey of HIV Infected Infected Patients Over 50: Implications for Nursing Care Objectives Julie Gumowski, RN, BSN Margaret Caplan, M.D. November 17, 2012 SAIC Frederick To discuss the prevalence

More information

Current Clinical Therapies for HIV Remission. David Margolis MD UNC HIV Cure Center

Current Clinical Therapies for HIV Remission. David Margolis MD UNC HIV Cure Center Current Clinical Therapies for HIV Remission David Margolis MD UNC HIV Cure Center Aiming for sustained remission off ART Cohen J. Science 214 Luzuriaga et al. NEJM 3;8: 786 Effect of vorinostat, hydroxychloroquine

More information

Surveillance, Thailand

Surveillance, Thailand BED-CEIA HIV Sero-incidence Surveillance, Thailand 2007-2011 2011 Window 127 day (subtype AE) FRR 0.05 BUREAU OF EPIDEMIOLOGY DEPARTMENT OF DISEASE CONTROL MINISTRY OF PUBLIC HEALTH, THAILAND Limitations

More information

CORSO DI AGGIORNAMENTO E.C.M.

CORSO DI AGGIORNAMENTO E.C.M. CORSO DI AGGIORNAMENTO E.C.M. RAZIONALE HIV Medicine is an ever-changing field: what today seems to be up-to-the-minute treatment often tomorrow is already out of date! Progress continues to be particularly

More information

What s New in Acute HIV Infection?

What s New in Acute HIV Infection? 3 4 Disclosure I have received research grants awarded to my institution from Gilead Sciences, Inc. ntiretroviral medications have been provided by Gilead Sciences, Inc. Susan Little, M.D. Professor of

More information

A Summary of Clinical Evidence

A Summary of Clinical Evidence A Summary of Clinical Evidence Supporting the use of the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test to assist in the diagnosis of Human Immunodeficiency Virus (HIV) TAP HERE TO SEE THE PRODUCTS Table

More information

DEFENSE HEALTH AGENCY 7700 ARLINGTON BOULEVARD, SUITE 5101 FALLS CHURCH, VIRGINIA

DEFENSE HEALTH AGENCY 7700 ARLINGTON BOULEVARD, SUITE 5101 FALLS CHURCH, VIRGINIA DEFENSE HEALTH AGENCY 7700 ARLINGTON BOULEVARD, SUITE 5101 FALLS CHURCH, VIRGINIA 22042-5101 DHA-IPM 18-020 MEMORANDUM FOR ASSISTANT SECRETARY OF THE ARMY (MANPOWER AND RESERVE AFFAIRS) ASSISTANT SECRETARY

More information

Pediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER

Pediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,

More information

Pre-Exposure Prophylaxis (PrEP) for HIV Infection

Pre-Exposure Prophylaxis (PrEP) for HIV Infection Pre-Exposure Prophylaxis (PrEP) for HIV Infection Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health University of California Los Angeles Attending Physician UCLA Center AIDS Research

More information

The how and why of Acute HIV Infection 1. How do we best diagnosis patients with acute HIV?

The how and why of Acute HIV Infection 1. How do we best diagnosis patients with acute HIV? Acute HIV infection Eric Rosenberg, MD Associate Professor of Pathology Director, Clinical Microbiology Laboratory Massachusetts General Hospital Harvard Medical School The how and why of Acute HIV Infection

More information

Promoting early detection of HIV and anal dysplasia in Thai men who have sex with men Phanuphak, N.

Promoting early detection of HIV and anal dysplasia in Thai men who have sex with men Phanuphak, N. UvA-DARE (Digital Academic Repository) Promoting early detection of HIV and anal dysplasia in Thai men who have sex with men Phanuphak, N. Link to publication Citation for published version (APA): Phanuphak,

More information

Mathematical-Statistical Modeling to Inform the Design of HIV Treatment Strategies and Clinical Trials

Mathematical-Statistical Modeling to Inform the Design of HIV Treatment Strategies and Clinical Trials Mathematical-Statistical Modeling to Inform the Design of HIV Treatment Strategies and Clinical Trials Marie Davidian and H.T. Banks North Carolina State University Eric S. Rosenberg Massachusetts General

More information

OR: Steps you can take in the clinic to prevent HIV infections

OR: Steps you can take in the clinic to prevent HIV infections Implementing Changes to Reduce HIV Incidence: Synergies between Public Health and Primary Care Kevin Ard, MD, MPH Brigham and Women s Hospital, Massachusetts General Hospital, and the Fenway Institute

More information

Continuing Education for Pharmacy Technicians

Continuing Education for Pharmacy Technicians Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected

More information

HIV Pathogenesis and Natural History. Peter W. Hunt, MD Associate Professor of Medicine University of California San Francisco

HIV Pathogenesis and Natural History. Peter W. Hunt, MD Associate Professor of Medicine University of California San Francisco HIV Pathogenesis and Natural History Peter W. Hunt, MD Associate Professor of Medicine University of California San Francisco Learning Objectives Describe key features of HIV pathogenesis and natural history

More information

HEALTH SERVICES POLICY & PROCEDURE MANUAL

HEALTH SERVICES POLICY & PROCEDURE MANUAL PAGE 1 of 5 PURPOSE To provide guidelines on the treatment and care of patients with Hepatitis. POLICY Hepatitis is an injury to hepatic cells and an inflammatory process in the liver. The major causes

More information

ART and Prevention: What do we know?

ART and Prevention: What do we know? ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:

More information

HIV depletes T-helper17, we simply stimulate it. By Prof. Dr.Pichaet Wiriyachitra Ph.D., F.R.A.C.I.

HIV depletes T-helper17, we simply stimulate it. By Prof. Dr.Pichaet Wiriyachitra Ph.D., F.R.A.C.I. HIV depletes T-helper17, we simply stimulate it By Prof. Dr.Pichaet Wiriyachitra Ph.D., F.R.A.C.I. Natural Healthcare for HIV infected HIV depletes T-helper17, we simply stimulate it Dr.Pichaet Wiriyachitra

More information

DISCOVERY OF FALSE HIV ELITE CONTROLLERS AMONG SOUTH AFRICAN BLOOD DONORS

DISCOVERY OF FALSE HIV ELITE CONTROLLERS AMONG SOUTH AFRICAN BLOOD DONORS DISCOVERY OF FALSE HIV ELITE CONTROLLERS AMONG SOUTH AFRICAN BLOOD DONORS ISBT TTID WP 17 June 2017 Marion Vermeulen, Karin van den Berg, Genevieve Jacobs, Brian Custer, Ronel Swanevelder, Ute Jentsch,

More information

PROSPECTS FOR HIV CURE IN ADULTS. Nov 11 th 2013 John Frater

PROSPECTS FOR HIV CURE IN ADULTS. Nov 11 th 2013 John Frater PROSPECTS FOR HIV CURE IN ADULTS FIS 2013 Nov 11 th 2013 John Frater April 29 th 2013; Telegraph online THE COMPONENTS OF A CURE. What is cure? Issues to consider: Post treatment control the benefit of

More information

Exploratory Age-stratified Analysis of Risk-taking Behaviors and Trial Participation Outcomes in the Thai Phase III HIV Vaccine Trial

Exploratory Age-stratified Analysis of Risk-taking Behaviors and Trial Participation Outcomes in the Thai Phase III HIV Vaccine Trial RV RV 144 Exploratory Age-stratified Analysis of Risk-taking Behaviors and Trial Participation Outcomes in the Thai Phase III HIV Vaccine Trial J Kaewkungwal, P Pitisuttithum, S Nitayapan, D. Stablein,

More information

Management of Severe Primary HIV Infection

Management of Severe Primary HIV Infection Management of Severe Primary HIV Infection Martin Fisher Brighton and Sussex University Hospitals Outline What is severe PHI? How frequent is severe PHI? Is this occurring more frequently? Is severe PHI

More information

CTLA-4-expressing CD4 T cells are critical contributors to SIV viral persistence

CTLA-4-expressing CD4 T cells are critical contributors to SIV viral persistence IAS 2015 Towards an HIV Cure symposium Vancouver CTLA-4-expressing CD4 T cells are critical contributors to SIV viral persistence Colleen McGary Paiardini lab Emory University HIV reservoir prevents eradication

More information

VARIABLES INFLUENCING ANTI-HUMAN IMMUNO- DEFICIENCY VIRUS TYPE 1 NEUTRALIZING HUMAN MONOCLONAL ANTIBODY (NhMAb) PRODUCTION AMONG INFECTED THAIS

VARIABLES INFLUENCING ANTI-HUMAN IMMUNO- DEFICIENCY VIRUS TYPE 1 NEUTRALIZING HUMAN MONOCLONAL ANTIBODY (NhMAb) PRODUCTION AMONG INFECTED THAIS VARIABLES INFLUENCING ANTI-HUMAN IMMUNO- DEFICIENCY VIRUS TYPE 1 NEUTRALIZING HUMAN MONOCLONAL ANTIBODY (NhMAb) PRODUCTION AMONG INFECTED THAIS Siriwat Akapirat 1,2, Anchalee Avihingsanon 3,4, Jintanat

More information

HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial

HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3, Nicola Robinson 1,2,3, Sarah Fidler 4, Jonathan

More information

Hepatitis C in HIV Coinfection. Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF

Hepatitis C in HIV Coinfection. Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Hepatitis C in HIV Coinfection Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Disclosures I have received research grant support to UCSF related to HCV from the following: Abbvie

More information

HIV: What Every Clinician Needs to Know ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING CONFERENCE BETTIE COPLAN MARCH 2018

HIV: What Every Clinician Needs to Know ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING CONFERENCE BETTIE COPLAN MARCH 2018 HIV: What Every Clinician Needs to Know ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING CONFERENCE BETTIE COPLAN MARCH 2018 Overview Overview recent trends in HIV incidence in the U.S. HIV screening

More information

HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body

HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University

More information

Mathematical-Statistical Modeling to Inform the Design of HIV Treatment Strategies and Clinical Trials

Mathematical-Statistical Modeling to Inform the Design of HIV Treatment Strategies and Clinical Trials Mathematical-Statistical Modeling to Inform the Design of HIV Treatment Strategies and Clinical Trials 2007 FDA/Industry Statistics Workshop Marie Davidian Department of Statistics North Carolina State

More information

I. HIV Epidemiology. HIV Infection A Primer. Objectives. Disclosures 7/18/2014

I. HIV Epidemiology. HIV Infection A Primer. Objectives. Disclosures 7/18/2014 Objectives HIV Infection A Primer Discuss the worldwide and domestic epidemiology of HIV infection Review HIV Biology Review HIV Transmission and Prevention Review HIV diagnosis Describe the approaches

More information

Novel Heterologous Prime-Boost Vaccine Strategies for HIV. Dan Barouch April 18, 2012

Novel Heterologous Prime-Boost Vaccine Strategies for HIV. Dan Barouch April 18, 2012 Novel Heterologous Prime-Boost Vaccine Strategies for HIV Dan Barouch April 18, 2012 Desired Features of a Next Generation HIV-1 Vaccine Candidate The RV1 study suggests that an HIV-1 vaccine is possible

More information

Primary HIV Infection: Clinical Presentation, Testing, and Treatment

Primary HIV Infection: Clinical Presentation, Testing, and Treatment Curr Infect Dis Rep (2017) 19: 37 DOI 10.1007/s11908-017-0588-3 HIV/AIDS (C YOON, SECTION EDITOR) Primary HIV Infection: Clinical Presentation, Testing, and Treatment Aurélia Henn 1,2 & Clara Flateau 1

More information

PRELIMINARY RYAN WHITE HIV/AIDS PROGRAM CLINICAL CARE CONFERENCE AGENDA

PRELIMINARY RYAN WHITE HIV/AIDS PROGRAM CLINICAL CARE CONFERENCE AGENDA PRELIMINARY RYAN WHITE HIV/AIDS PROGRAM CLINICAL CARE CONFERENCE AGENDA 9:00 9:15 AM Welcome and Introductions TUESDAY, DECEMBER 15, 2015 9:00 AM 5:05 PM 9:15 9:45 AM Update on the Ryan White HIV/AIDS

More information

Supersensitive Viral Load Assay in Predicting CD4-Guided Treatment Failure

Supersensitive Viral Load Assay in Predicting CD4-Guided Treatment Failure The Open Virology Journal, 2008, 2, 69-73 69 Open Access Supersensitive Viral Load Assay in Predicting CD4-Guided Treatment Failure Simone Langford a,, Angele Gayet-Ageron b,, Chris Duncombe a, Thidarat

More information

HIV Clinical Nurse Specialist CCDHB Wellington

HIV Clinical Nurse Specialist CCDHB Wellington RN James Rice-Davies HIV Clinical Nurse Specialist CCDHB Wellington 11:00-11:55 WS #88: Undiagnosed HIV in Your Practice 12:05-13:00 WS #99: Undiagnosed HIV in Your Practice (Repeated) HIV- Undiagnosed

More information

PrEP in the Real World: Clinical Case Studies

PrEP in the Real World: Clinical Case Studies PrEP in the Real World: Clinical Case Studies Kevin L. Ard, MD, MPH April 30, 2015 Massachusetts General Hospital, National LGBT Health Education Center Continuing Medical Education Disclosure Program

More information

HIV Prevention Strategies HIV Pre-exposure prophylaxis

HIV Prevention Strategies HIV Pre-exposure prophylaxis HIV Prevention Strategies HIV Pre-exposure prophylaxis Michael Martin, MD, MPH Director HIV Research Program Thailand MOPH U.S. CDC Collaboration The findings and conclusions in this presentation are those

More information

Antiretrovirals for HIV prevention:

Antiretrovirals for HIV prevention: Antiretrovirals for HIV prevention: Topical PrEP, Systemic PrEP and Treatment for Prevention Presentation at 6th International workshop on HIV treatment, pathogenesis and prevention research in resource-limited

More information

Case Studies in PrEP Management. Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016

Case Studies in PrEP Management. Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016 Case Studies in PrEP Management Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016 Continuing Medical Education Disclosure Program Faculty: Kevin

More information

Lopinavir Hair Concentrations Predict Virological Failure Among Asian Children

Lopinavir Hair Concentrations Predict Virological Failure Among Asian Children Lopinavir Hair Concentrations Predict Virological Failure Among Asian Children Wasana Prasitsuebsai, Stephen J. Kerr, Truong Huu Khanh, Jintanat Ananworanich, Do Chau Viet, Nguyen Van Lam, Nia Kurniati,

More information

Acyclovir for ear infections

Acyclovir for ear infections Acyclovir for ear infections The Borg System is 100 % Acyclovir for ear infections User feedback about Acyclovir side effects covering chicken pox, fatigue, shingles, hair loss, HSV2, dosage, anemia, ear

More information

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (Genvoya Gilead Sciences Canada, Inc.) Indication: HIV-1 Infection Recommendation:

More information

Recent advances in development and application of assays/algotithms for detection of recent HIV infections and estimation of incidence

Recent advances in development and application of assays/algotithms for detection of recent HIV infections and estimation of incidence Recent advances in development and application of assays/algotithms for detection of recent HIV infections and estimation of incidence Michael Busch, MD, PhD Blood Systems Research Institute University

More information

HIV care engagement among people with a history of injection drug use

HIV care engagement among people with a history of injection drug use HIV care engagement among people with a history of injection drug use Ann N. Burchell, PhD Scientist, Dept of Family and Community Medicine and Li Ka Shing Knowledge Institute St. Michael s Hospital burchella@smh.ca

More information